Form 4: Alto Neuroscience's Chief Medical Officer, Adam Savitz, Reports Stock Option Grant

Adam Savitz, Chief Medical Officer of Alto Neuroscience, reported the acquisition of stock options on March 1, 2024.

Summary

• Adam Savitz, the Chief Medical Officer of Alto Neuroscience, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 1, 2024, where Savitz acquired options to purchase 73,000 shares of Alto Neuroscience common stock at an exercise price of $14.88.
• These options vest over time, with 25% vesting on March 1, 2025, and the remainder vesting monthly over the following 48 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the one described (25% after one year, then monthly), are common to incentivize long-term commitment.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates